McDermott Represents Ampersand Capital Partners in Business Combination of Vivitide and Biosynth Carbosynth - McDermott Will & Emery

McDermott Represents Ampersand Capital Partners in Business Combination of Vivitide and Biosynth Carbosynth


International law firm McDermott Will & Emery represented Ampersand Capital Partners, a healthcare-focused private equity fund, in its investment with KKR, a leading global investment firm, in the business combination of Biosynth Carbosynth, an innovative life sciences reagents, custom synthesis and manufacturing services company, and Vivitide Inc., a global leader in custom peptides and antibody services. Together, KKR and Ampersand plan to accelerate the company’s geographic expansion, broaden its capabilities and expand its product portfolio.

  • Biosynth Carbosynth manufactures and sources a vast range of chemical and biochemical products, specializing in carbohydrates, nucleosides, phospholipids, enzyme substrates, antimicrobials, APIs and natural products and have a full range of reagents for protein production and analysis. Vivitide is a global provider of custom peptides, antibody services, and catalog products for the life science and biotech industry and provides a broad portfolio of custom peptide synthesis services, custom antibodies, catalog peptides and biochemicals.
  • Ampersand Capital Partners will roll over its entire stake in Vivitide Inc. and become a substantial minority shareholder of the combined entity.
  • The cross-border US, UK, Germany and Belgium McDermott team was led by Kristian Werling, Lindsey Reighard and Calum Thom with corporate support from John Prinzivalli, Simon Margesson, Christian Marzlin, Michael Cziesla, Deniz Tschammler, Lea Hachmeister, Lisa Schickling, Jana Grieb, Gudrun Germakowski and Lukas Deutzmann. Hendrik Viaene led the global regulatory approval process with support from Carina Kant and Anja Bertrand. Global tax structuring was led by Michael Bruno with support from Alejandro Ruiz and the finance team was led by Anh Lee with support from Libby Jacobson.
  • Read Ampersand Capital Partners and KKR’s combined press release here.

McDermott’s private equity practice is among the top four most active PE law firms globally and in the US with more than 160 dedicated private equity lawyers in 21 locations globally. In addition to being Pitchbook’s top Healthcare PE firm for a fourth consecutive year and fifth in both IT and financial services private equity, we are named Energy & Industrials Law Firm of the Year (Large Cap) by The Deal, Top 10 in PE Buyouts by MergerMarket and Top 10 in US Mid-Market by Bloomberg. Learn more about our PE practice by visiting

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts